Search
Diphenylpyraline H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175106Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeLevocabastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175129Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeClofedanol H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175145Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeZuclopenthixol H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175153Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeMepyramine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175094Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeClemastine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0058891Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeKetotifen H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175083Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeBrompheniramine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175082Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeDoxepin H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175110Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha typeCyclizine H1-Antihistamine Immune Response Action Pathway
smpdb.ca/view/SMP0175088Drug actionReducing the activity of the NF-κB immune response transcription factor through the phospholipase C and the phosphatidylinositol (PIP2) signalling pathways also decreases antigen presentation and the expression
Enzymes: Protein kinase C beta type, Protein kinase C alpha type